In August, the company revived its “Best Deal Ever” promotion, offering a large pizza with any toppings for just $9.99.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
So far, 2025 has been one of the choppiest ever for the business of wood thanks to tariffs and a housing market slowdown.
A nuclear boom is directly downstream from the AI boom, with $350 billion in nuclear spending in the US planned by 2050, per Bloomberg.
The acquisition comes as new CEO Mike Doustdar tries to revive once meteoric growth that has come crashing down to earth this year.
The Atlanta-based carrier expects to make record earnings in the fourth quarter, with an adjusted profit of $1.60 to $1.90 a share.
When First Brands filed for bankruptcy last month, it listed over $10 billion in liabilities and nearly $6 billion in long-term debt.
The new Model Y, dubbed the Model Y Standard, essentially fills the void of the expired tax credit with a starting price of $39,990.
Just 54% of US adults said they consume alcohol in a recent Gallup poll, marking the lowest level in the survey’s roughly 90-year history.
As AI platforms take the place of search engines, a move into shopping could further upend the established tech order.
The company is on a mission to open 10,000 new locations over the next four years, bringing its worldwide total to 50,000.
In fact, the EV credit expiration sparked a record one sales quarter, with the company delivering 497,099 vehicles worldwide.
Walmart — a.k.a., the largest grocer in the United States — sells so many groceries it’s nearly impossible to keep track.
Universal and Warner are said to be pushing AI startups to develop an attribution system that can track when an artists’ music is used.
Car vending machines are all the rage this year, with shares in the firm behind the novel notion, Carvana, soaring this year.
Sales of new electric vehicles fell 6.3% year-over-year in the second quarter, according to Cox Automotive analysts.
A 2024 RAND study found that US drug prices are 278% higher than in 33 other developed countries in the OECD.